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Cancerprincipal oncogene of murine polyomavirus. Its study has led to the discovery of
the roles of tyrosine kinase and phosphoinositide 3-kinase (PI3K) signaling in mammalian growth control
and transformation. MT is necessary for viral transformation in tissue culture cells and tumorigenesis in
animals. When expressed alone as a transgene, MT causes tumors in a wide variety of tissues. It has no
known catalytic activity, but rather acts by assembling cellular signal transduction molecules. Protein
phosphatase 2A, protein tyrosine kinases of the src family, PI3K, phospholipase Cγ1 as well as the Shc/Grb2
adaptors are all assembled on MT. Their activation sets off a series of signaling cascades. Analyses of virus
mutants as well as transgenic animals have demonstrated that the effects of a given signal depend not only
tissue type, but on the genetic background of the host animal. There remain many opportunities as we seek a
full molecular understanding of MT and apply some of its lessons to human cancer.
© 2008 Elsevier Inc. All rights reserved.An introduction to MT and this reviewSince its discovery in 1953, polyomavirus has served as a model
system for the study of transformation mechanisms and cellular
signaling. Murine polyoma's role in signaling research arises from a
quirk of evolution that created an extra reading frame in the early region
of the virus. The resulting third early protein was designated middle T
antigen (MT) on the basis of its apparentmolecularweight. Unlike small
T (ST) and large T (LT) antigens, whichwork in transformation primarily
by acting on host tumor suppressor proteins such as p53, pRb and
protein phosphatase 2A (PP2A), MT acts by activating key proto-
oncogenes involved in cellular signaling. In this way MT effectively
mimics a constitutively activated receptor tyrosine kinase (RTK). Its
primary structure is diagrammed below in Fig. 1. Mechanistically, MT,
like an RTK, ﬁrst binds and activates a tyrosine kinase. In the case of the
RTK, a ligand is used to bind a secondRTK, thus activating bothmembers
of the ligand induced dimer. MT binds and activates amember of the src
family of non receptor tyrosine kinases using both a motif on MT and a
portion of the PP2A phosphatase as a scaffold. The activated src family
kinase in turn phosphorylates MT on key tyrosines generating docking
sites for cellular signaling molecules—a process which is conceptually
identical to the signaling mechanism of a ligand activated RTK. Notably
studies of MT have signiﬁcantly contributed to our understanding ofDepartment of Cancer Biology,
2 4770.
Schaffhausen),
l rights reserved.cellular signal transduction. Thus, the ﬁrst tyrosine kinase assays were
conducted on MT immunoprecipitates as were the key early experi-
ments on PI3 kinase (for another review see Dilworth, 2002). With
inhibitors of PI3K now entering the clinic it may soon be possible to
credit studyof this viral oncogene as contributing to cancer therapy, thus
delivering on the early promise of tumor virology to the war on cancer.
In the following review we will examine MT's role in transforma-
tion and signaling in more detail. While space does not permit a full
historical record of each of these studies, we will attempt to track the
history of key parts of the story. After an overview, our narrative will
roughly follow the diagram in Fig. 1 from the amino to carboxyl
terminus and ﬁnish with a short consideration of animal studies.
Overview of MT function and structure
MT is the key to polyomavirus transformation. It is always necessary
for virus transformation (Carmichael et al., 1982; Templeton and Eckhart,
1982). MT is in many cases sufﬁcient (Treisman et al., 1981) for
transformation of cells in tissue culture. Where it is not sufﬁcient, MT
canbe complementedbyavarietyof oncogenesgenerally thought toact in
the nucleus, such as LT (Land, Parada, and Weinberg, 1983), E1A (Ruley,
1983),myc (Land et al.,1983) and p53 (Utermark et al., 2007), aswell as ST
(Moule et al., 2004; O'Shea and Fried, 2005), which acts on the p53
pathway. The importance of MT in polyomavirus tumor induction is clear
(Asselin et al.,1984; Cullere et al., 1998; Freund et al., 1992a,1992c).When
expressed as a transgene, MTcauses tumors in a variety of tissues (Aguzzi
et al.,1990;Bautch,1989;Duetal., 2006;Guyet al.,1992; Lewiset al., 2005;
Rassoulzadegan et al., 1990; Tehranian et al., 1996). MT has been a
Fig. 1. Landmarks on MT. Sites of interaction of MT with cellular proteins are shown. Each of the signal transducers shown below the middle T sequence is known to be important for
transformation. PP2A=protein phosphatase 2A, PTK=src family tyrosine kinase (src, yes, fyn), PI3K=phospholinositide 3-kinase, and PLCγ=phospholipase Cγ1. There can also be
interaction between Gab1 and PI3K. PPP represents the proline rich/E349K sequence important for transformation. Simple versions of signaling pathways downstream of Y250, Y315
and Y322 are shown. The light blue area represents the hydrophobic membrane attachment site.
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associations with host proteins have generally had clear phenotypes in
transformation (Cullere et al., 1998; Freund et al., 1992a). By comparison,
the effects ofmutations of single tyrosinephosphorylation sites ongrowth
factor receptors, such as the PDGFr, have been harder to evaluate.
Besides its role in transformation, MT also plays an important role
in polyoma infection (Freund et al., 1992c; Garcea et al., 1989;
Templeton et al., 1986). These effects can occur at different levels. A
defect in viral assembly associated with altered phosphorylation of
VP1, which responds to MT (Li and Garcea, 1994), can be observed in
hr-t mutants lacking MT (Garcea and Benjamin, 1983). MT also
participates in regulating both viral DNA replication and RNA
transcription (Chen and Fluck, 2001; Chen et al., 1995, 2006).
MT has 421 amino acids. Since the T antigens are produced by
differential splicing of common early transcripts, MT shares 79 amino
acids that represent a DnaJ domain with both LT and ST, as well as an
additional 112 amino acids with ST. There is a stretch of 22
hydrophobic residues that represent a membrane anchor sequence
at the C-terminus. The ability of MT to transform depends on its
association with membranes (Carmichael et al., 1982). MT has no
known catalytic activity, but rather functions as a scaffold on which
cellular signaling proteins are assembled and activated. It binds the A
and C subunits of protein phosphatase 2A (PP2A) (Pallas et al., 1990;
Walter et al., 1990). As a result of this association, MT is able to bind
protein tyrosine kinases (PTKs) of the Src family (Src, Yes, Fyn) (Cheng
et al., 1988a; Courtneidge and Smith, 1983; Horak et al., 1989;
Kornbluth et al., 1987). In the PTK complex, MT is phosphorylated on
three major tyrosine residues: 315, 322 and 250 (Carmichael et al.,
1984; Harvey et al., 1984; Hunter et al., 1984; Schaffhausen and
Benjamin, 1981a). Each of these sites represents a connection to a
signal generator: 315 to phosphoinositide 3-kinase (PI3K) and one or
more additional interacting proteins (Hong et al., 2003; Kaplan et al.,1986; Whitman et al., 1985), 250 to Shc (Campbell et al., 1994;
Dilworth et al., 1994) and thence to Grb2 and SOS, and 322 to
PLCgamma1 (Su et al., 1995). However, this picture of three tyrosine
phosphorylation sites is not complete. Additional minor tyrosine
phosphorylation sites may also contribute to MT function (Chen et al.,
2006). Finally, serine phosphorylation at 257, which controls associa-
tion with the 14-3-3 family, affects the ability of MT to cause salivary
gland tumors (Cullere et al., 1998). We will discuss each of these
interactions and their role in MT signaling and transformation in turn.
MT and PP2A
MT (and ST) binds protein phosphatase 2A (PP2A) (Pallas et al.,
1990; Walter et al., 1990). Mutational analysis of MT indicates that
sequences near the N-terminus (Glenn and Eckhart, 1995), in the
region from 111–120 (Campbell et al., 1995; Glenn and Eckhart, 1993),
in the area from 142 through the conserved WFG motif at 157
(Campbell et al., 1995; Martens et al., 1989 and Li and Schaffhausen,
unpub.) and through NG59 mutation at 179 (Cheng et al., 1986; Silver
et al., 1978) or a deletion of residues 180–190 (Brewster et al., 1997)
can all affect PP2A binding. Some of these residues are in cysteine
motifs that are expected, based on SV40 ST structures (Chen et al.,
2007; Cho et al., 2007) to be involved in zinc binding (Rose and
Schaffhausen,1995). PP2A is one of themajor cellular serine/threonine
protein phosphatases (Janssens and Goris, 2001; Janssens et al., 2005;
Millward et al., 1999; Mumby, 2007). It functions as a trimeric ABC
complex, where a scaffold A subunit brings together the catalytic
subunit (C) and one of a large family of regulatory B subunits (Fig. 2A).
There are two isoforms each of A and C, while there are four B families,
each with several members. MT binds to the A and C subunits (Pallas
et al., 1990; Walter et al., 1990), displacing or preventing B subunits
from binding (Fig. 2B). Since structural analysis shows that SV40 ST
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2007; Cho et al., 2007), the apparent absence of B subunits in Py/PP2A
complexes is unsurprising. MT binds both A alpha and A beta isoforms
of PP2A, while SV40ST in comparison binds only the A alpha form
(Zhou et al., 2003). While the functional consequence of this
difference is unclear, mutations in PP2A A beta have been associated
with lung and colon cancer (Ruediger et al., 2001;Wang et al., 1998). It
also appears that A beta is involved in regulating the RalA GTPase
(Sablina et al., 2007).
There is an obvious and critical role for PP2A in MT function.
Association of MT with PP2A is required for association with the Src
family PTKs (Brewster et al., 1997; Campbell et al., 1995; Ogris et al.,
1999), so PP2A- MT is unable to transform (see the section on Src
kinases below). Interestingly, PP2A catalytic activity seems not to be
required (Ogris et al., 1997) to promote binding of PTKs. This suggests
that PP2A is part of a scaffold that allows src to bind to MT. There has
also been a suggestion based on a study of a PP2A binding mutant of
MT (Brewster et al., 1997) that PP2A binding affects the intracellular
location of MT. However, there is a problem in interpreting this kind of
experiment. Because abrogation of the ability of MT to bind PP2A
allows hsc70 to bind (Campbell et al., 1995), hsc70 binding might well
affect intracellular localization. There is also a report that MT uses
PP2A to activate c-jun kinase (Mullane et al., 1998).
The obvious role of PP2A in src recruitment has perhaps led
investigators away from detailed examination of the catalytic roles of
PP2A in MT action. This is probably short-sighted. PP2A is involved in
many cellular processes, including transcription, translation and
replication. At least 50 protein kinases are regulated by PP2A
(Millward et al., 1999), and it functions as a tumor suppressor
(Janssens et al., 2005; Westermarck and Hahn, 2008). Decreasing the
activity of PP2A towards myc has been associated with head and neck
carcinoma and colon cancer (Junttila et al., 2007). This raises the
question of howMTchanges the activity of PP2A. There are some hints
from ST studies. SV40ST inhibits PP2A activity in many situations
(Scheidtmann et al., 1991; Yang et al., 1991). In some situations, such as
transformation of kidney cells (Chen et al., 2004), knock-down of
speciﬁc B subunits mimics some of the effect of SV40ST in causing
transformation, while overexpression of B subunits can reverse some
of the effect of SV40ST. While there is certainly not enough MT to
titratemost or all of the cell's PP2A, even reducing the available pool of
subunits to create a situation of haploinsufﬁciency affects the
spectrum of PP2A complexes (Chen et al., 2005). However, it is also
important to note that perturbation of PP2A function by SV40ST
increases the activity of PP2A towards certain substrates, such as
histone H1 (Yang et al., 1991) or the androgen receptor (Yang et al.,
2005). Such effects are likely to contribute to the transformed
phenotype as well. The idea would be that MT could target PP2A
towards speciﬁc substrates. There is now evidence that lipin, forFig. 2. MT and PP2A:PP2A exists as heterotrimeric ABC complexes. (A) There are two
different A subunit scaffolds to which two different catalytic C subunits could bind.
There aremany different B family regulatory subunits. (B) The binding of PyST (or PyMT)
replaces B subunits.example, is a substrate dephosphorylated as a result of its interaction
with MT (B. Schaffhausen, unpublished).
MT and the Src family of tyrosine kinases
As noted in the Introduction, the ﬁrst tyrosine kinase assays were
carried out onMT immunoprecipitates (Eckhart et al., 1979). Only later
was it determined that kinase activity associated with MT comes from
binding protein tyrosine kinases (PTKs) of the src family (src, yes fyn)
(Cheng et al., 1988a; Courtneidge and Smith, 1983; Horak et al., 1989;
Kornbluth et al., 1987). However, MT does not associate with all
members of the src family. Thus, it fails to bind lck (Louie et al., 1988)
or hck (Dunant et al., 1996). The tyrosine kinase activity coming from
association with src kinases is critical for transformation (Carmichael
et al., 1984; Eckhart et al., 1979; Harvey et al., 1984; Schaffhausen and
Benjamin, 1979; Smith et al., 1979). Manipulating the level of tyrosine
kinase activity either by regulating MT levels (Raptis et al., 1985) or
manipulating src with anti-sense affected the degree of transforma-
tion (Amini et al., 1986). It appears that association with particular
family members may be differentially important in speciﬁc tissues. In
Fisher rat cells, it has been estimated that 50–75% of the activity is
from src and the remainder from the other kinase complexes (Bolen et
al., 1987). In a transgenic MT model of mammary carcinoma, src is the
functionally important partner (Guy et al., 1994). For hemangiomas,
although single knockouts of src, yes or fyn do not block MT tumor
formation, yes knockouts respond much more weakly to MT, with
fewer tumors and longer latency (Kiefer et al., 1994; Thomas et al.,
1993).
The association with the src family PTKs is unusual in a number of
respects. Only small fractions (∼10%) of MT and src are in MT/src
complexes (Bolen et al., 1987). Furthermore, overexpression of either
partner is not effective at driving complex formation (Cook et al., 1990;
Piwnica-Worms et al., 1986; Schaffhausen et al., 1987). Finally, the
interaction between MT and src is slow, taking hours to complete
(Cohen et al., 1990).
Src itself has several domains organized in the following order: an
N-terminal myristylation sequence, a unique domain, an SH3 domain,
an SH2 domain and a catalytic domain with a C-terminal tail that
contains a regulatory phosphorylation site at Y527. Phosphorylation at
527 provides a binding site for the src SH2 that results in restricted
activity. MT needs only the catalytic domain and C-terminal sequences
for association (Dunant et al., 1996). The C-terminal sequences around
the regulatory phosphorylation site are important for binding: a
truncation at 516 fails to bind MT (Cartwright et al., 1987), mutations
in the C-terminal region abolish binding and v-src that has an altered
C-terminus also fails to bind (Cheng et al., 1988b). It appears that
additional sequences further N-terminal are also required, since a src–
lck fusion, where the C-terminus comes from lck (that itself does not
bind MT), nonetheless binds MT (Louie et al., 1988). Dunant et al. have
investigated the failure of hck to bind MT (Dunant et al., 1996). Based
on their observations on a C-terminal Y501 hck mutant, they
concluded that MT was unable to bind to a closed conformation
which had a pY/SH2 interaction, but rather would bind to an open
conﬁguration. In support of this idea, they presented data arguing that
src that had the SH2 domain deleted showed enhanced MT binding.
MT mutations that affect src binding have been found in a number
of areas. The primary binding site on MT for binding PTKs has been
deﬁned genetically as lying between residues 185–210, with 2 basic
motifs followed by an S or T playing important roles (Brewster et al.,
1997; Glover et al., 1999). However, other regions also seem to be
important to form the MT/PTK complex. Mutations near the N-
terminus of MT (Cook and Hassell, 1990; Glenn and Eckhart, 1995;
Templeton and Eckhart, 1984b), in the J domain (Whalen et al., 2005),
and in the PP2A binding site (Campbell et al., 1995; Schaffhausen and
Benjamin, 1979) also disrupt assembly of MT/PTK complexes. In
general, these results support the idea that PP2A binding is required
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(Whalen et al., 2005) has been reported to bind PP2A. L5E (Glenn and
Eckhart, 1995) is a different kind of exception in that it has been
reported to bind a phosphatase, apparently different from PP2A, but
still to bind src. Some PP2A inhibition experiments (Glover et al., 1999)
and a report suggesting that PP2A might be able to dephosphorylate
phosphotyrosine (Cayla et al., 1993) might suggest a catalytic role for
PP2A in formation of the MT–PTK complex. However, examination of
catalytically dead PP2A C subunit has shown that it can support MT/
src complex formation (Ogris et al., 1997).
Src bound toMT is activated (Bolen et al., 1984; Courtneidge,1985),
showing a substantial increase in the Vmax of kinase activity. Src in the
MT complex is also unphosphorylated at the C-terminal 527Y
(Cartwright et al., 1986; Courtneidge, 1985). These observations
were key to the general understanding of how src kinase activity is
negatively regulated (Cartwright et al., 1987; Cooper et al., 1986;
Kmiecik and Shalloway, 1987; Piwnica-Worms et al., 1987). At the
same time src is phosphorylated on Y416 in MT complexes, a site
known to be activating (Cartwright et al., 1986). Interestingly, there
also appears to be additional N-terminal sites of src tyrosine
phosphorylation in MT complexes (Cartwright et al., 1986; Yonemoto
et al., 1985). However, these additional sites (Y138 and Y213) are
known to respond to growth factors and may regulate SH3 and SH2
interactions respectively (see Roskoski, 2005 for a review).
In the case of transformation by v-src, there is a dramatic increase
in total ptyr in the transformed cells (Hunter and Sefton, 1980). There
is not a broad general increase in tyrosine phosphorylation in MT
transformed cells (Sefton et al., 1980), although treatment of cells with
vanadate, a tyrosine phosphate inhibitor, led to a signiﬁcant increase
over the controls (Yonemoto et al., 1987). Some src targets, such as
stat3 (Garcia et al., 1997) seem to be activated by MT, while others,
such as p34, do not (Cheng and Chen, 1981). MT itself is perhaps the
most important substrate. In the PTK complex middle T is phosphory-
lated on tyrosine residues, including major sites at 315, 322 and 250
(Harvey et al., 1984; Hunter et al., 1984; Schaffhausen and Benjamin,
1981b). Some phosphorylation is observed at 297 and possibly 258 as
well (unpublished). These phosphorylations connect MT to different
signaling pathways that will be discussed in turn.
The tyrosine 250 phosphorylation site binds Shc
There is no question that MT is phosphorylated at tyrosine 250 in
the MT/PTK complex (Hunter et al., 1984). However, in many respects
the role of this residue is enigmatic. In many in vitro assays of
transformation,mutation of tyrosine 250 (Markland et al.,1986; Ong et
al., 2001; Utermark et al., 2007) as well as mutations in the region
amino terminal to 250 (the NPTYmotif) (Druker et al., 1990; Druker et
al., 1992) have a dramatic effect on transforming ability. As will be
discussed below, the 250 site leads to the recruitment of the adaptor
Shc (Campbell et al., 1994; Dilworth et al., 1994). In the transgenic
mammary tumors induced by MT, mutation of tyrosine 250 also has a
profound effect on tumor formation (Webster et al., 1998). Tumor
studies in virus-infected animals have also conﬁrmed a role for the 250
site in polyoma tumorigenesis (Bronson et al., 1997; Yi et al., 1997). The
frequency of kidney tumors, for example, is dramatically reduced in
250 mutants. On the other hand, there are cells such as human
mammary epithelial cells and ﬁbroblasts where mutation of Y250 to F
has no effect on transformation (Utermark et al., 2007). Even different
clones of F111 rat embryo ﬁbroblasts show different sensitivity to
Y250F mutations (Ong et al., 2001). In contrast to the transgenic
experiments in the mammary gland, virus experiments in mice with
Y250S show little, if any difference, in the frequency of mammary
tumors (Bronson et al., 1997; Yi et al., 1997), although there were
differences in the morphological types of tumors (Yi et al., 1997). The
virus experiments also showed that Y250S mutants could produce
larger tumors than wild type, for example in hair follicle tumors thatwere more than 100× larger in volume than wild type, or produce a
greater frequency (2/3 of mice) of tumors such as penile papillomas
that are quite rare after infection with wild type virus (Bronson et al.,
1997). As in many other situations, such results indicate the
importance of context in signaling.
The most immediate and obvious role for the Y250 phosphoryla-
tion is to provide a docking site for the ShcA family of adaptors
(Campbell et al., 1994; Dilworth et al., 1994). The ShcA family includes
three overlapping isoforms of p46, p52 and p66 kDa (Pelicci et al.,
1992). p46 and p52 are ubiquitous, while p66 is more restricted and
subject to epigenetic regulation (Ventura et al., 2002). All 3 isoforms
share a domain structure that has a N-terminal PTB domain and a C-
terminal SH2 domain, both of which can potentially bind phosphotyr-
osine sequences (Schlessinger and Lemmon, 2003), as well as a central
proline-rich CH1 region. While the data are clearest for p52, MT
appears to bind and affect all 3 family members. The PTB domain is
clearly important for bindingMT. Shc PTBs bindΨXNPXpYmotifs (van
der Geer et al., 1995, 1996a). Mutation of these residues in MT clearly
affects its ability to bind and affect Shc phosphorylation as well as
transform (Campbell et al., 1994; Druker et al., 1990, 1992). Over-
expression of the Shc PTB domain inhibits MT transformation of
NIH3T3 cells (Blaikie et al., 1997). However, since MT has also been
reported to bind to the Shc SH2 in vitro (Dilworth et al., 1994) and
since P248H, but not Y250F, induced a small amount of Shc tyrosine
phosphorylation in vivo (Campbell et al., 1994), the possibility of some
SH2 interaction cannot be excluded.
Although only a small fraction of p52 is bound to MT in
immunoprecipitates, a signiﬁcant fraction of total p52 is phosphory-
lated upon MT expression (Campbell et al., 1994). Shc is tyrosine
phosphorylated on at least 3 sites, Y317 (Y313 in mouse) (Salcini et al.,
1994) and a double phosphorylation site at Y239/Y240 (van der Geer et
al., 1996b). Phosphospeciﬁc antibodies show that MT affects both of
these sites (Jiang, Zhu and Schaffhausen, unpubl.) It has been suggested
(e.g. Gotoh et al., 1996) that these two phosphorylation sites have
distinct functions, but this issue has never been examined for MT. It is
known that expression of Y239F/Y240F Shc, but not Y317F Shc, affects
the size of agar colonies of MT transformed cells (Blaikie et al., 1997).
Both the Y317(Y313) site (Salcini et al.,1994) and theY239/Y240 site
(van der Geer et al., 1996b) have been reported to bind Grb2. Each of
these sites has been reported to recruit the Grb2 adaptor. It is therefore
unsurprising that MT promotes the association of Shc with Grb2
(Campbell et al., 1994; Dilworth et al., 1994) and that Grb2 is found in
MT immunoprecipitates (Nicholson et al., 2001). The MT sequence
around Y250 has been replaced with Shc sequences (313 or 239/240)
known to bind Grb2. This has been done either at the same location or
between residues MT 281–284, a region not thought to be important
forMT transformation. For transformationof Rat2 cells, insertion of the
239/240 sequence was more potent than the 313 sequence (Nicholson
et al., 2001). However, since some substitutions did not fully
recapitulate wild type function, even when binding amounts of Grb2
comparable towild type, the authors concluded that Shc probably does
more than interactwithGrb2. Replacing theNPTY sequence ofMTwith
a GRB binding sequence (either YVNQ or YYD) stimulated the
production of hemangiomas and the introduction of both sequences
worked best, with tumor latenciesmatching that of wild typeMT (Ong
et al., 2001). In transgenic experiments, overexpressing Grb2 (or Shc)
reduced the timeneeded for tumoronsetwithMT Y250F from111days
to 80 days (or 94 days) (Rauh et al., 1999).
The recruitment of Grb2 allows the binding of additional proteins.
One of these is the adaptor Gab1 (Nicholson et al., 2001; Ong et al.,
2001). Gab1 plays an important role in signaling of a number of
growth factors and cytokine receptors (Nishida and Hirano, 2003). Of
potential importance, Gab1 is involved in the recruitment of PI3-
kinase. This will be discussed further in the next section. Gab1 would
also be expected to bind the SHP-2 tyrosine phosphatase and the
adaptor Crkl. The binding of Grb-2 leads to the recruitment of SOS
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to lead to Ras activation, which is, in fact observed (Srinivas et al,
1994). Once Ras is activated this should lead to Raf, MEK, ERK
activation, and then to p90rsk or transcription factors such as Elk. In
fact, little published conﬁrmation of ERK activation by MT is available
except in unusual situations such as HL60 cells undergoing differ-
entiation (Yen et al., 1999). There is evidence that Shp2 is also
connected to growth factor activation of ERK (Nishida and Hirano,
2003). Whether the Gab1 interaction connects Shp2 regulation of ERK
is an open question.
Tyrosine 315 and PI3K
The principle role of tyrosine 315 when phosphorylated is to bind
particular isoforms of PI3 Kinase (PI3K). Here we recount in a largely
historical fashion how MT allowed identiﬁcation of PI3 kinases. We
also take the liberty of describing the subsequent realization that
PI3Ks were a potential drug target in human tumors. The next few
years should tell if PI3K inhibition will have therapeutic effects in
cancer.
Before the discovery of PI3K, tyrosine 315 was one of the ﬁrst sites
on MT to be examined by site directed mutagenesis with unexpect-
edly mixed results. Two groups made identical Tyr315 to Phe
mutations, and then expressed the mutant proteins in different cell
types using different expression systems. When expressed via
polyoma virus infection of F111 rat cells, the 315 mutant was almost
totally inactive in transformation (Carmichael et al., 1984); when
transfected in Rat-1 cells as a plasmid construct expressing only MT,
the 315mutant was almost as effective in transformation as wild type
MT (Oostra et al., 1983). Although this difference was never totally
resolved, it is likely simply the ﬁrst case of a common theme in MT
transformation and signaling: the importance of cellular context to
signaling outcome and requirements. The true signiﬁcance of Tyr315
could be realized only upon the discovery of its binding partner, PI3K
(Whitman et al., 1985).
PI3Ks are a family of lipid kinases distinguished from one another
by their substrates, cellular functions and subunit composition. The
Class 1A PI3Kswere ﬁrst studied as a phosphatidylinositol kinase (PIK)
activity in partially puriﬁed preparations of the oncoprotein pp60v-src
(Sugimoto et al., 1984). A similar activity was found in immunopre-
cipitates of MT, which by that time was known to function by binding
and activating pp60c-src (Kaplan et al., 1986; Whitman et al., 1985).
However, oncogene-associated PIK activity was only a small fraction of
the total PIK activity in the cell and, thus, was considered by many to
be an artifact of isolation. The importance of the PI kinase was a
subject of considerable controversy for some time. Notably, however,
the PIK activity was found associated with all transformation
competent alleles of MT, but not with a number of non-transforming
alleles including deletions or point mutants of Y315 (Kaplan et al.,
1986). In time, it was realized that the small fraction of MT-bound PIK
activity possessed unique biochemical properties, designated type I
PIK, which distinguished it from the bulk of the PIK in the cell
(Whitman et al., 1987). The presence of the type I PIK activity in
immunoprecipitates of MT was tightly correlated with the presence of
an 85 kDa polypeptide (Kaplan et al., 1987). More importantly, both
the type 1 PIK and p85 were soon found to be physically associated
with a variety of activated receptor tyrosine kinases, and once again
genetic experiments, using mutants which failed to bind the PI kinase,
suggested that the association was essential for the biological
functions of both RTKs and oncoproteins (Escobedo et al., 1991;
Kaplan et al., 1987; Varticovski et al., 1989). With the cloning of the
gene for p85, it became clear that p85 is an SH2 containing adaptor
protein designed to couple the type I PIK to activated RTKs and
oncoproteins such as MT via its interactions with speciﬁc phospho-
tyrosine motifs (Escobedo et al., 1991; Hu et al., 1992). In the case of
MT this is the sequence phosphoYMPM starting at Tyr315 on MT.Further analysis showed that there were actually 2 genes p85α and
p85β, encoding highly similar proteins which both bind MT (Cohen et
al., 1990). To date no distinction in the functions of p85α/β have been
found for MT, even though knock-out studies have shown the 2
proteins to have distinct roles in development (Fruman et al., 1998). As
an aside, we note that the association between MTand the N-terminal
SH2 of p85 provided a prototype for establishing speciﬁcity of SH2
domains (Songyang et al., 1993) and a structural model that showed
how NMR can be used to demonstrate ligand induced conformation
intermediates during high afﬁnity binding (Gunther et al., 2002;
Mittag et al., 2004). The next ﬂurry of discoveries identiﬁed and
characterized the p110 catalytic subunits of the type I PIKs. Classical
PIKs were known to phosphorylate phosphatidylinositol (PI) on the 4′
position on the inositol ring to generate PI(4)P. However, it was
noticed that type 1 PIK associated with MT could use PI(4)P as a
substrate (Whitman et al., 1988), suggesting that type1 PIK was not
simply phosphorylating the 4′ position on the inositol ring. Instead,
the type 1 enzyme was shown to phosphorylate the 3′ position on the
inositol ring to generate PI(3,4)P2, thus leading to its renaming as PI3K
(Whitman et al., 1988). Puriﬁed PI3K associated with RTKs and
oncoproteins was found to consist of two subunits: the p85 adaptor
plus a catalytic subunit of 110 kDa (Carpenter et al., 1990).With further
puriﬁcation and molecular cloning of PI3Ks, it became clear that there
was actually a family of PI3Ks (Hiles et al., 1992; Hu et al., 1993). The
family was divided into three groups: Class I PI3Ks, which could use PI,
PI(4)P, and PI(4,5)P2 as substrates in vitro; Class II PI3Kswhich utilized
PI and PI(4)P; and Class III PI3Ks, restricted to PI as a substrate (see
reviews by Fruman et al., 1998 and Vanhaesebroeck and Waterﬁeld,
1999). Notably, Class1 enzymes seem to be limited to the use of PI(4,5)
P2 as a substrate in vivo. Class I was further divided into three Class IA
enzymes, each consisting of the p85 adaptor subunit complexed with
one of three p110 catalytic subunits (α, β, and δ) and capable of
associating with RTKs and oncoproteins, and Class IB, a single species
that features a different subunit composition and is largely conﬁned to
leukocytes. The discovery in the late 1990s that ﬁrmly established the
Class 1A PI3Ks as oncogenes was the ﬁnding that p110α had been
captured by an avian retrovirus rendering it oncogenic (Chang et al.,
1997).
After the discovery of PI3K, it was some time before the
downstream signaling targets of PI3K were identiﬁed. Over time
however it became clear that the role of PIP3 was to lure certain PH
(pleckstrin homology) domain containing proteins to the membrane
via a direct interaction of the PH domain and PIP3. Among the key
targets are the ser/thr kinase PDK1 and its downstream target the ser/
thr kinase Akt. Akt in turn phosphorylates a large number of targets
regulating cell growth, DNA synthesis, chemotaxis and apoptosis. As
might be expected MT can activate Akt (Dahl et al., 1998; Meili et al.,
1998; Summers et al., 1998) and Rac (Denis and Schaffhausen,
unpublished). Activation of Akt by MT prevents apoptosis (Dahl et
al., 1998; Meili et al., 1998). The functional consequences of Akt
activation have been demonstrated most elegantly in the MMTV-MT
mammary tumor model (see below).
Also activated via a PH domain-containing nucleotide exchange
protein is the small GTP binding rac (for a review see Bustelo et al.,
2007). Dominant-negative Rac activation blocks transformation of
both ﬁbroblasts (Urich et al., 1997) and endothelial cells (Connolly et
al., 2000). It appears that Rac activation is necessary for MT to activate
c-fos (Chen et al., 1999; Urich et al., 1997).
The discovery that the tumor suppressor PTEN actually works by
antagonizing PI3K showed the ﬁrst direct link between PI3K activation
and human cancer. After the positional cloning of PTEN, it was
immediately obvious from its sequence that it was a phosphatase (Li et
al., 1997; Steck et al., 1997). While it possessed protein tyrosine
phosphatase activity (Li et al., 1997), it was subsequently shown that
PTENwas also a lipid phosphatase capable of speciﬁcally removing the
3′ phosphate from PI(3,4,5)P3 (Maehama and Dixon, 1998). Further
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its function as a tumor suppressor (reviewed by Vazquez and Sellers,
2000). Thus, PTEN seems to be designed as a brake for the Class 1
PI3Ks. Not surprisingly, PI3K signaling was found to be highly
activated in PTEN-null tumor cell lines and primary tumors. Overall,
PTEN is inactivated in a high percentage of common human cancer
types including tumors of the prostate (30–50%) (Cairns et al., 1997),
brain (at least 30%) (Chiariello et al., 1998) and breast (more than 20%)
(Feilotter et al., 1999).
While the discovery of the lipid phosphatase activity of PTEN had
heightened interest in PI3K as a potential drug target in cancer, the
importance of this class of enzymes in cancer was ﬁxed with the
discovery that the PIK3CA gene encoding p110αwasmutated at a high
frequency in a number of themost common forms of cancer, including
colon, breast, prostate, liver, and brain tumors (Samuels and
Velculescu, 2004). Studies in several model systems have showed
that the mutations commonly found in p110α in human tumors are
indeed activating (Isakoff et al., 2005; Kang et al., 2005; Samuels et al.,
2005; Zhao et al., 2005). Notably, mutations have not been found in
the genes encoding the other Class 1 PI3Ks, even though several
groups have demonstrated that these enzymes are capable of acting as
oncogenes in model systems (Kang et al., 2005; Zhao et al., 2005).
However the PIK3CB gene, encoding p110β, has been found to be
ampliﬁed in several tumor types.
As drug companies prepare to attack the pathway, an examination
of what we have learned from genetic mouse models and chemical
genetics might contribute to designing optimal inhibitors for PI3K.
Traditional knock-out of p110δ or knock-in of an inactive form of p110δ
yieldsmice that grow to adulthood but show severely impaired Tand B
cell function (Jou et al., 2002; Okkenhaug et al., 2002). Genetic ablation
of either p110α or p110β gives an early embryonic lethal phenotype (Bi
et al., 2002; Bi et al., 1999), limiting the information that can be gained
about the roles of these isoforms in adults. However, while hetero-
zygous knock-out of either p110α or p110β had no effect on insulin
signaling, mice with heterozygous loss of both isoforms showed a
noticeably impaired insulin response (Brachmann et al., 2005). Recent
studies have used either conditional knock-out of p110α (Zhao et al.,
2006) or heterozygous knock-in of a kinase dead allele of p110α (the
homozygous knock-in is, as expected, early embryonic lethal) (Foukas
et al., 2006) to show that p110α is essential for most RTK signaling and
for normal insulin function in animals. When p110β was examined
againvia knock-in of a kinase dead allele or via conditional knock-out, a
very different picturewas seen. Unlike p110α, loss of p110β has little or
no effect on RTK signaling as usuallymeasured (Jia et al., 2008). Instead
p110β is essential for GPCR (G protein coupled receptor) signaling (Jia
et al., 2008, Guillermet-Guibert et al., 2008). Surprisingly, p110β also
seems to play a role in insulin action in vivo. Even more surprising is
the fact that the knock-in allele is viable (E. Hirsch, inpress), suggesting
that p110b has a kinase independent function. Studies in mouse
embryo ﬁbroblasts (MEFs) using a conditional allele support this idea
and suggest that the kinase independent function might play a role in
membrane trafﬁcking (Jia et al., 2008).
MT antigen is once again an important part of the PI3K story as the
search begins to ﬁnd which p110 isoforms are important to tumor
formation. Mice with ﬂoxed alleles of p110s are now being bred into a
variety of mouse models for cancer. Early results are in for MT and a
number of receptor tyrosine kinases in standard MEF transformation
system (Utermark et al., 2007). Here it has been found that ablating
p110α alone is sufﬁcient to slow, or in the case of MT, completely block
tumor growth. Notably these p110 knock-outs have ﬁnally allowed
conﬁrmation that PI3K is actually essential to MT transformation
(Utermark et al., 2007), a nontrivial question since the SH2 domains of
other signaling molecules bind sequences similar to the motif at Y315.
Other studies are being carried out in genetic mouse models where
surprisingly knock-out of p110α has been found to have little effect in
a PTEN driven prostate tumor model while ablation of p110β has beenfound to greatly diminish tumorigenesis in the anterior lobe (Jia et al.,
2008). Clearly more studies will be required to ﬁnd which isoform is
the better target in a given tumor type.
The pharma industry has not overlooked the potential importance
of PI3K as a drug target in cancer. A large number of companies are
now moving aggressively to test PI3K inhibitors in the clinic. Since
most if not all of the ﬁrst inhibitors in the clinic will block all p110
isoforms (and perhaps other kinases related to the PI3Ks as well),
some target-directed side effects may be encountered. These might
include impaired immune function due to loss of p110δ function as
well as problems in insulin response due to inhibition of p110α.
However, none of the known side effects of a pan inhibitor need limit
its potential therapeutic usefulness, especially if such an inhibitor can
be used for a relatively limited course of treatment (perhaps weeks or
months instead of the years of treatment employed for some protein
kinase inhibitors).
PLCγ1 binding to tyrosine 322
The role of tyrosine 322 in PLCγ binding was ﬁrst recognized by Su
et al. (1995), who made their initial observations based on the
similarity of the YLDI motif at tyr322 with the then known preferred
binding peptides for the SH2 domains of PLCγ. While expression ofMT
in murine ﬁbroblasts clearly results in enhanced tyrosine phosphor-
ylation of PLCγ, it has been difﬁcult to see MT mediated activation of
signaling pathways downstream from PLCγ including activation of
PKCs or enhanced calcium release. Mutation of Y322 to F resulted in
reduced focus formationwhen the assay was performed in low serum
but not in normal serum. However, expression of MT in the Jurkat T
cell line did result in a clear ampliﬁcation of stimuli, which normally
activate calcium signaling and NFAT. This enhanced calcium signaling
was dependent on Y322 (Kennedy et al., 1998). In mice, regulated
expression of a dominant negative allele of PLCγ markedly decreased
lung metastases in the MMTV-MT breast tumor model without
altering the primary tumors (Shepard et al., 2007).
Other MT binding proteins
TAZ
MT binds theWWdomain of TAZ through amino acid residues 2–4
(Tian et al., 2004). First reported as a 14-3-3 binding protein, TAZ
functions in transcriptional regulation (Hong et al., 2005) and also can
promote protein degradation through a SCFβ-Trcp E3 ligase complex
(Tian et al., 2007). TAZ modulates mesenchymal stem cell differentia-
tion (Honget al., 2005), promotes cell proliferation (Lei et al., 2008) and
functions in tumorigenesis of breast cancer cells (Chan et al., 2008).
Unpublished reports indicate that a polyomavirus mutant defective in
TAZ binding) is unable to transform and induce tumors (Tian et al.,
2007). However, such a mutant would also be defective in ST– and LT–
TAZ interactions, so how much of the effect is from MT is not certain.
Heat shock 70 family proteins
Most of the ﬁrst exons (79 amino acids) common to MT, LT and ST
comprise a classic DnaJ domain. As such, these proteins would be
expected to bind and activate the hsp70/hsc70 family of DnaK cellular
heat shock proteins. Infection with either SV40 or polyoma induces
the expression of the heat shock proteins (Khandjian and Turler,1983).
For LT, hsc70 binding is known to happen and to be important for
activation of E2F-containing promoters (Sheng et al., 1997). While MT
might be expected to bind to hsp/hsc70, it appears that PP2A binding
and Hsc binding are largely mutually exclusive, with PP2A found
bound to the majority of both ST and MT when the viral proteins are
expressed at levels found in transformed cells. At high levels of
expression of MT, as might be seen upon expression via an adenovirus
Fig. 3. The sequence at the C-terminus of MT is responsible for association with
membranes. The hydrophobic sequence is underlined. Residue 393 that is discussed in
the text and residue 384 that is the last residue found in non-transforming, cytoplasmic
Py1387T are indicated.
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mutation (Campbell et al., 1995; Walter et al., 1987), hsp/hsc70
proteins can indeed be immunoprecipitated with the viral protein. As
noted above, the DnaJ domain is important for the recruitment of
PP2A and src. However, this does not appear to result from binding
and activation of DnaK proteins. Deletion analysis has shown that
removal of a key loop with the amino acid sequence HPDK has no
effect on the ability of MT to transform (Campbell et al., 1995; Glenn
and Eckhart, 1995).
14-3-3 proteins
MT binds 14-3-3 proteins (Pallas et al., 1994) through an
interaction at phosphoserine 257 (Cullere et al., 1998). The interaction
with 14-3-3 provides an illustration of the importance of tissue
context. While not important at most sites, the interaction appears
critical for the induction of salivary gland tumors by polyoma virus
and important for the generation of ﬁbrosarcomas (Cullere et al.,
1998).
The proline-rich region
The C-terminal region of MT contains a proline rich region from
residue 332–347 (Fig. 1). The mutant dl1015 that has a deletion in this
region (339–347) is defective in transformation (Magnusson and Berg,
1979; Magnusson et al., 1981). This mutant has a normal tyrosine
kinase activity associated with it (Schaffhausen and Benjamin, 1981c).
Deletion of the three core prolines (residues 336–338) yields a MT
defective in inducing tumors in animals (Yi and Freund, 1998). The
basis for the defect in transformation is unclear. Identiﬁcation of a
point mutant E349K that mimics the defect (Schaffhausen and Denis,
unpublished) suggests PI3 kinase signaling is interrupted between
recruiting the enzyme and its downstream signaling.
Finally, it should be noted that several laboratories are pursuing
proteomic approaches that are revealing additional MT binding
proteins, such as lipin 1 and 2 (Schaffhausen et al. unpublished).
The MT-membrane connection
MT is associated with membranes (Andrews et al., 1993; Ballmer-
Hofer and Benjamin, 1985; Dilworth et al., 1986; Ito, 1979; Ito et al.,
1977; Schaffhausen et al., 1982; Silver et al., 1978; Zhu et al., 1998). The
only portion of the MT sequence long enough and hydrophobic
enough to span a lipid bilayer is very close to the C-terminus (Fig. 3).
Mutation that renders MT cytoplasmic by truncating prior to the
hydrophobic stretch (Py1387T) abolishes its ability to transform
(Carmichael et al., 1982). Truncation of 6 amino acids into the C-
terminal side of the hydrophobic stretch renders MT non-transform-
ing (Novak and Grifﬁn, 1981).
There is agreement that MT can be associated with a variety of cell
membranes. However, the apparent distribution of MT depends on the
way that the experiment has been done. Immunoﬂuorescence and
immunoelectronmicroscopy experiments have emphasized association
with intracellular membranes, particularly the endoplasmic reticulum
(Dilworth et al., 1986; Templeton et al., 1984; Zhu et al., 1984), while
biochemical separations have focused more on associationwith plasma
membranes (Ito, 1979; Schaffhausen et al., 1982). In either case, most of
the MT molecule is oriented towards the inside of the cell. The
orientation of the hexapeptide C-terminus is not yet clear. In either
case, MT appears not only to be in contact with membranes, but also
with membrane skeleton/cytoskeletal elements (Andrews et al., 1993;
Krauzewicz et al., 1994; Schaffhausen et al.,1982). This sublocalization is
likely to be important for function, because MT/PTK complexes are
enriched in these fractions (Schaffhausen et al.,1982). Elliott et al. (1998)
have provided evidence suggesting that the basic cluster N-terminal to
the hydrophobic cluster is important for this localization.The original examination of the membrane anchoring sequence for
MT suggested that it might spontaneously associate with membranes
in a manner analogous to cytochrome b5. However, in vitro model
membrane binding experiments (Kim et al., 1997) suggest that MT
carboxy terminal sequences do not spontaneously insert into
membrane as does cytochrome b5, but are able to associate
electrostatically. The same result is obtained when the anchor
sequence is placed on another protein, implying that the rest of the
MT sequence is not inhibiting. These results may well suggest that
associationwith one or another MT partner is responsible for allowing
its insertion into the bilayer.
The transmembrane domain is not uniquely required for MT
transformation. Replacement of the hydrophobic sequencewith the C-
terminal lipid modiﬁcation sequence from H-Ras (a CaaX box)
restored transforming activity (Elliott et al., 1998). However, the role
of the membrane localization sequence is not entirely non-speciﬁc
either. Substitution of VSV-G protein sequences (Templeton et al.,
1984) or cytochrome b5 (Kim et al., 1997) sequences to target MT to
membranes did not allow MT transformation. Similarly substitutions
within the hydrophobic domain rendered MT non-transforming
(Markland et al., 1986). A truncation mutant that leaves basic cluster
on MT, while lacking the hydrophobic stretch, is still associated with
particulate fractions including cytoskeletal fractions (Elliott et al.,
1998). In any case, those insertion sequence mutants are intriguing
because they activate src to some extent, but are nonetheless non-
transforming (Markland et al., 1986).
Genetic analyses of the regions adjacent to the hydrophobic stretch
have also been performed. The hexapeptide (KRSRHF) C-terminal to
the hydrophobic sequence can be deleted without affecting transfor-
mation of F111 rat embryo ﬁbroblasts (Dahl et al., 1992). However, the
N-terminal basic region appears more important. As noted above, that
region has been suggested to be important for connection to the
cytoskeleton (Elliott et al., 1998). E392G is cold sensitive for
transformation (Templeton and Eckhart, 1984a). Mutation R393E
just N-terminal to the hydrophobic sequence yields a mutant that is
less completely localized to membranes than wild type (Dahl et al.,
1992). This mutant has only a weak focus forming activity and is
unable to promote anchorage independent growth (Dahl et al., 1992).
Both src (65%) and PI3 kinase (85%) activities are affected by the
mutation. Other substitutions (K, H, or M) at 393 had no effect.
Animal models of transformation driven by MT
No account of MT mediated transformation would be complete
withoutmention of themanymurine tumormodels dependent onMT.
Polyomavirus induces tumors in numerous tissues in themouse (Dawe
et al., 1987). A great advantage of the system is that signal transduction
questions can be tested by tumor studies in animals. The most direct
method is by infecting with polyomavirus defective in MT (Bronson et
al.,1997; Cullere et al.,1998; Freund et al.,1992a; Freund et al.,1992c; Yi
and Freund, 1998; Yi et al., 1997). Not only do hr-t mutants defective in
MT and ST show defects in tumor formation (Benjamin, 1982), but
1387T that encodes a cytoplasmic MT mutant, but is wild type for LT
and ST, is highly defective in the ability to make tumors. A very
important conclusion from all of these studies is that mutations
affecting particular signaling pathways have different effects in
different tissues. Mutation of the PI3 kinase binding site resulted in a
20-fold reduction in kidney tumors, for example, but there was
actually an increase in the number of bone tumors in the mutant as
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seems to be critical in many transformation assays in vitro. However,
its contribution to the virus' tumor proﬁle is much less dramatic than
that of 315 (Bronson et al., 1997; Yi et al., 1997). While the frequency of
kidney tumors was dramatically reduced, tumor frequencies in the
mammary gland or hair follicles were notmuch affected. However, the
hair follicle tumors caused by themutant weremuch larger than those
fromwild type (Bronson et al.,1997). The interaction ofMTwith the 14-
3-3 proteins appears critical for the induction of salivary gland tumors
and important for the generation of ﬁbrosarcomas, but is not
important for tumorigenesis at most sites (Cullere et al., 1998).
To test MT in the context of virus requires that the mutant virus
replicates in animals. Even if the virus replication is normal, MT
signaling is still being tested in the context of LT and ST action on the
host. To test the role of MT directly, transgenic approaches have been
used. As a transgene MT causes tumors in a wide variety of tissues
(Aguzzi et al., 1990; Bautch et al., 1987; Cecena et al., 2006; Guy et al.,
1992; Rassoulzadegan et al., 1990; Tehranian et al., 1996; Williams et
al., 1988). Some of these models have been discussed brieﬂy above but
others deserve mention. In prostate for instance MT can induce fatal
prostate cancer (Tehranian et al., 1996). Expressed in endothelial cells,
MT induces hemangiomas. These tumors are especially interesting
because the transformed endothelial cells recruit non-transformed
endothelial cells into the tumors (Primo et al., 2000; Williams et al.,
1989). When expressed in mammary glands under control of the
MMTV promoter, MT efﬁciently induces metastatic carcinomas (Guy
et al., 1992). This much-used model will be discussed further below.
An obvious problem with a traditional transgenic approach to
studying tumor development is the time at which the oncogenic
signal is generated. One approach to getting around this problem is to
use conditional expression of Cre (Cecena et al., 2006) or some kind of
tetracycline regulation. An alternative would be to introduce MT via a
retrovirus. Historically an avian retrovirus carrying MT was used to
induce hemangiomas in chickens (Kornbluth et al., 1986). The current
methodology introduces MT into speciﬁc tissues using the RCAS-TVA
system developed by Varmus and colleagues (Fisher et al., 1999). Mice
have been derived that express the ALSV-A (TVA) avian retrovirus
receptors in speciﬁc tissues. When these mice are infected with RCAS
(Replication Competent ALV LTR with a Splice acceptor) viruses, only
cells expressing the receptor are infected. For MT, mammary tumors
(Du et al., 2006), liver tumors (Lewis et al., 2005) and pancreatic
tumors (Lewis et al., 2003) have been examined in this way. The
approach has now been extended to lentivirus constructs to allow
efﬁcient infection of non-dividing cells (Siwko et al., 2008).
MT transgenic systems have been extensively studied to under-
stand the process of tumorigenesis. The MMTV-MT mammary tumor
system originally developed by the Muller lab (Guy et al., 1992) has
been particularly widely studied (see Marcotte and Muller, 2008 for a
review). It provides a relatively goodmodel for the human disease (Lin
et al., 2003; Namba et al., 2004), even though, as noted by Marcotte
and Muller there are signiﬁcant differences from the human situation.
The mouse tumors are largely ERα negative, while 50% of human
tumors are positive, and the mouse tumors metastasize to the lung,
whereas human metastases are more broadly distributed. In the
MMTV-MT 634 line, by 5 weeks of age all mice had palpable tumors
that involved the whole mammary fat pad; 94% of females developed
metastatic lung disease by 3 months of age (Guy et al., 1992). Genetic
analysis indicates that src, but not yes, is important for the
development of MT tumors (Guy et al., 1994). Both the activation of
PI3K and Shc is thought to be important for MT tumorigenesis
(Webster et al., 1998). Tumor formation defects in a MT mutant 250
can be ameliorated by overexpression of either Shc or Grb2 (Rauh et
al., 1999). Akt is an important downstream target of PI3 kinase.
Ablation of Akt 1 inhibits, but ablation of Akt2 enhances, mammary
tumor formation by MT (Maroulakou et al., 2007). The experiments of
Webster described above also removed 322 from MT, but the role ofbinding to PLCγ has not been directly tested by mutation of only the
322 site. However, the expression of dominant negative Plcγ1 reduced
metastasis, suggesting that 322 might play a role in that process
(Shepard et al., 2007). Induction of metastasis seems to depend on the
production of osteopontin (Jessen et al., 2004), which is regulated by
MT at the transcriptional level through both Shc and PI3K (Whalen et
al., 2008). A remaining question is whether MT is functioning as “one-
hit” tumor inducer, or whether MT initiates a series of events that lead
to other genetic changes required for tumor formation. The high
frequency and short latency might seem to argue that MT is all that is
needed. On the other hand, there is obviously progression of the
lesions (Lin et al., 2003), and it is possible to isolate mammary
intraepithelial neoplasias that have different properties (Maglione et
al., 2004) and show different patterns of expression (Namba et al.,
2004, 2006). A difﬁculty in the interpretation of such experiments is
that it has long been known that the transformed phenotype varies
with the amount of T antigen expression (Raptis et al., 1985). Little is
known about the expression levels of MT protein in different lesions.
Studies on animals point out a variety of additional issues that need
to be considered when thinking about MT signaling. It is quite obvious
that the strain of mice being used makes a signiﬁcant difference. For
polyomavirus, there are large differences in susceptibility to tumor
formation (Freund et al., 1992b) that depend to a signiﬁcant extent on
differences in the nature of the immune response (Lukacher et al.,1993,
1995; Velupillai et al., 1999, 2002). In the transgenic models there are
also striking differences in latency andmetastatic potentialwhenMT is
expressed in different mouse strains (Lifsted et al., 1998; Winter and
Hunter, 2008). A bioinformatics approach has pointed to c-myc and
cdc25a as genes regulating latency (Cozma et al., 2002). Sipa1, which is
a Rap GAP has been implicated as a modiﬁer of metastasis (Park et al.,
2005). Finally, the interaction of MT cells with their neighbors will
affect the signaling patterns. As noted above, MT transformed
endothelial cells recruit non-transformed endothelial cells (Primo et
al., 2000;Williams et al., 1989). Adipocytes, one of the cell types of the
stroma in mammary tissue, can produce collagen VI that affects
primary MT tumor growth (Iyengar et al., 2005). Macrophages, for
example, seem to contribute to both progression andmetastasis in the
MT-MMTV system (Lin and Pollard, 2004). There appears to be a
signaling loop between tumor cells and macrophages that is involved
in tumor cell migration (Wyckoff et al., 2004).
Epilogue
By this point it should be apparent that the study of MT has
contributed much to our knowledge of signaling and transformation.
What must also be underscored is how much remains to be done. Not
only do we need to understand known binding proteins better, but
new proteins are being discovered by more modern and sensitive
proteomic technologies. The genetics of MT suggest that there are
important aspects of the signaling in transformation that are not yet
understood. The ability of MT transgenes to drive tumor formation in
so many tissues and the vast store of mouse lines combining MT with
other genetic lesions should enable MT transgenics to be excellent
models to decipher tissue and tumor speciﬁc roles of signaling
molecules, such as p110α/β, going forward. Another important
challenge is translating the tissue and mouse strain speciﬁc responses
that are known to occur into a molecular understanding of the
regulation of and by MT.
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